Synthetic Biologics, Inc. (NYSE
MKT: SYN), a developer of pathogen-specific therapies for serious infections
and diseases, with a focus on protecting the microbiome, today announced
positive topline safety and tolerability results from a Phase 1a clinical
trial of SYN-004, the Company's investigational oral beta-lactamase enzyme for
the prevention of Clostridium difficile (C. difficile) infection,
antibiotic-associated diarrhea and secondary antibiotic-resistant infections
in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Since December 2^nd, the randomized double-blind, placebo-controlled Phase 1a
clinical trial conducted at Clinical Pharmacology of Miami, has enrolled 24
healthy volunteers in three cohorts of eight patients each. A total of 18
volunteers have been administered one dose of SYN-004 at increasing dose
levels by cohort, and six volunteers received placebo. No clinically
significant or relevant adverse events have been reported to date.
"Completing the first safety review and reporting positive topline results in
the Phase 1a clinical trial of SYN-004 is an important event for Synthetic
Biologics, bringing us closer to the first potential point-of-care
preventative therapy for C. difficile, the CDC's top-ranking public health
threat. Achieving this milestone moves us closer to validating our
ground-breaking approach to preventing C. difficile infection in a way that
protects the gut microbiome, which also holds the hope of treating a variety
of GI, metabolic and CNS disorders," said Jeffrey Riley, Chief Executive
Officer of Synthetic Biologics.
Mr. Riley added, "Based on the results observed in the first three cohorts,
and per our clinical plan, we intend to proceed with our planned
multiple-ascending dose placebo-controlled Phase 1b study of SYN-004, in which
healthy volunteers will receive increasing doses of SYN-004 over several days.
We expect enrollment into our Phase 1b SYN-004 clinical trial to begin before
year-end, with topline data available during the first quarter of 2015. We
also expect to initiate enrollment in a Phase 2 SYN-004 clinical trial ahead
of schedule during the first quarter of 2015."
SYN-004 is Synthetic Biologics' oral drug candidate designed to be the first
and only treatment intended to prevent C. difficile infection. Its mechanism
of action is to bind with and neutralize certain common IV beta-lactam
antibiotics in the gut. During 2012, 14.4 million U.S. patients received
approximately 117.6 million doses of IV antibiotics[i] that could be
inactivated in the gastrointestinal (GI) tract by SYN-004. SYN-004 is intended
to block the unintended harmful effects of antibiotics within the GI tract,
maintaining the natural balance of the bacterial flora (gut microbiome),
potentially preventing the 1.1 million C. difficile infections[ii] and 30,000
C. difficile-related deaths[iii] in the United States each year.
The U.S. Centers for Disease Control (CDC) has identified C. difficile as an
"urgent public health threat" and occurs mostly in people who have had recent
medical care with IV antibiotics. These antibiotics can create a harmful
imbalance in the gut microbiome by killing "good" bacteria, giving C.
difficile a chance to multiply and cause diarrhea, which can lead to
dehydration, fever, abdominal pain, cramping, nausea, colitis, and even death.
In all, 24 million Americans receive IV antibiotics annually[iv].
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in